All posts by: Michael Zand

About Michael Zand

Promising Immunotherapy Approaches in AML – OncLive

Continue reading

2018-03-19 NEWS

OncLive

Promising Immunotherapy Approaches in AML
OncLive
I think the most exciting thing is not only these novel drugs targeting immunotherapy and microenvironment coming down the pike, but I also see now that we have known active agents, and a lot of the discussion that I’ve seen at this conference is how

and more »

Continue reading

2018-03-19 NEWS

Genetic Literacy Project

FDA puts clinical hold on Solid Biosciences’ gene therapy trial for Duchenne muscular dystrophy over toxicity concerns
Genetic Literacy Project
The FDA has imposed a full clinical hold on Solid Biosciences’ Phase I/II trial for its lead candidate, the Duchenne muscular dystrophy (DMD) gene therapy SGT-001, the company acknowledged. GNITE DMD had been on a partial clinical hold since November
Financial Contrast: Solid Biosciences (SLDB) & Its PeersThe Ledger Gazette

all 18 news articles »

Continue reading

2018-03-19 NEWS

World’s Most Expensive Shampoo Triple Stem Cell Shampoo
PR Newswire (press release)
Amazing Moisture® Shampoo contains cutting edge combination of beneficial stem cells plus the powerful healing and nourishing properties of specific botanical extracts and extremely mild coconut cleansers. All are formulated in a base of certified

Continue reading

2018-03-19 NEWS

MaSTherCell Appointed as Process Development and Manufacturing Partner for Zelluna Immunotherapy’s TCR …
Markets Insider
GERMANTOWN, Md., March 19, 2018 (GLOBE NEWSWIRE) — Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that its manufacturing subsidiary, MaSTherCell S.A. (“MaSTherCell”) was

Continue reading

2018-03-19 NEWS

MaSTherCell Appointed as Process Development and Manufacturing Partner for Zelluna Immunotherapy’s TCR …
Markets Insider
GERMANTOWN, Md., March 19, 2018 (GLOBE NEWSWIRE) — Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that its manufacturing subsidiary, MaSTherCell S.A. (“MaSTherCell”) was

Continue reading

2018-03-19 NEWS

MaSTherCell Appointed as Process Development and Manufacturing Partner for Zelluna Immunotherapy’s TCR …
GlobeNewswire (press release)
GERMANTOWN, Md., March 19, 2018 (GLOBE NEWSWIRE) — Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that its manufacturing subsidiary, MaSTherCell S.A. (“MaSTherCell”) was

and more »

Continue reading

2018-03-19 NEWS

MaSTherCell Appointed as Process Development and Manufacturing Partner for Zelluna Immunotherapy’s TCR …
GlobeNewswire (press release)
GERMANTOWN, Md., March 19, 2018 (GLOBE NEWSWIRE) — Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that its manufacturing subsidiary, MaSTherCell S.A. (“MaSTherCell”) was

and more »